# A Long-term Safety and Tolerability Study of USL261 in Patients With Seizure Clusters

> **NCT02161185** · PHASE3 · TERMINATED · sponsor: **UCB Biopharma S.P.R.L.** · enrollment: 7 (actual)

## Conditions studied

- Epilepsy

## Interventions

- **DRUG:** USL261

## Key facts

- **NCT ID:** NCT02161185
- **Lead sponsor:** UCB Biopharma S.P.R.L.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-05
- **Primary completion:** 2015-05
- **Final completion:** 2015-05
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** Study terminated due to slow enrollment. There were no safety concerns.
- **Last updated:** 2019-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02161185

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02161185, "A Long-term Safety and Tolerability Study of USL261 in Patients With Seizure Clusters". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02161185. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*